Popular Trials
Monoclonal Antibodies
Crizanlizumab for RVCL
Recruiting1 awardPhase 2
Saint Louis, Missouri
This trial tests crizanlizumab, a medication that prevents blood cells from sticking to vessel walls, in patients with a rare and fatal condition called RVCL. The goal is to see if it can reduce brain and eye damage by preventing small blood vessel blockages. Crizanlizumab is a monoclonal antibody developed by Novartis Pharmaceuticals for the prevention of vaso-occlusive crises in patients with sickle cell disease.
Chemotherapy
Stem Cell Transplantation for Osteopetrosis
Recruiting1 awardPhase 2
Minneapolis, Minnesota
This trial tests a treatment using busulfan and fludarabine to prepare patients with certain genetic disorders for a bone marrow transplant. The goal is to safely replace their bone marrow with healthy donor cells by carefully monitoring drug levels. Busulfan is used to clear out bone marrow cells before the transplant, and fludarabine is being tested as a less harmful alternative to another drug.
Popular Filters
Trials With No Placebo
Radioactive Tracer for Multiple Sclerosis
Recruiting1 awardPhase 1
Bethesda, Maryland
This trial tests whether a radioactive tracer (minibody) can help identify certain immune cells in people w/ MS & PML. Eligible participants aged 18+ must come to clinic for 3 visits over 4-6 weeks for physical & neurological exams, MRI, & PET scan.
ABBV-CLS-7262 for Vanishing White Matter Disease
Recruiting1 awardPhase 1 & 2
Salt Lake City, Utah
This trial is testing a new drug called ABBV-CLS-7262 in adults and children aged 6 years or older who have Vanishing White Matter disease. The study will last for almost two years and will involve frequent medical check-ups to see if the drug helps improve their condition.
Virus Therapy
VGL101 for Leukoencephalopathy
Recruiting1 awardPhase 2
Englewood, Colorado
This trial is testing iluzanebart, a medication given through infusions, in adults with a specific genetic mutation causing ALSP, a rare brain disease. The goal is to see if the medication is safe and can slow down the disease by looking at brain scans and other health markers. Participants will receive the treatment regularly for a year, with an option to continue for additional years.
Antiplatelet Agent
Cilostazol for Cerebral Small Vessel Disease
Recruiting1 awardPhase 1 & 2
Jacksonville, Florida
This trial aims to test cilostazol, a medication that prevents blood clots and improves blood flow, in older adults with cerebral small vessel disease (SVD). The study will evaluate if cilostazol can slow the progression of SVD by improving blood flow and reducing inflammation. Participants will undergo various tests to measure changes in their condition over time.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.